About Tizona

Tizona is applying novel scientific insights to change the course of cancer progression and relapse

Our Leadership Team

We believe success comes from a team of cross-functional experts focused on a common vision. For us, it is improving treatment outcomes for people with cancer. Our employees, leadership, Board of Directors, advisors, partners and investors live it. We hope one day, so will patients.


Christine O’Brien

Chief Executive Officer

Courtney Beers, PhD

Chief Scientific Officer

John Corbin, PhD

Chief Technology Officer

Swami Murugappan, MD, PhD

Chief Medical Officer

Erin Johnson, PhD

Vice President, Program Leadership and Alliance Management

Board of Directors

Pankaj Bhargava, MD

Executive Partner, MPM Capital

Kurt von Emster

Managing Partner, Abingworth

William Grossman, MD, PhD

SVP, Gilead Sciences

Nina Kjellson

General Partner, Canaan Partners

Christine O’Brien

CEO, Tizona Therapeutics

Linda Slanec Higgins, PhD

SVP, Gilead Sciences

Dan Spiegelman

Chair, Tizona Therapeutics

Director, Myriad Genetics, Inc.

Former EVP & CFO, BioMarin Pharmaceutical Inc.

Scientific Co-founders & Advisory Board


mpm logo

canaan logo

abingworth logo

interwest logo

lightstone ventures logo

abbvie logo

amgen logo

astellas logo

gilead logo

Strategic Partnership

We are developing cancer treatments that have the potential to be first- and best-in-class treatments, and core components of immunotherapy combination regimens.

In August 2020, Tizona entered into a transformative alliance with Gilead Sciences whereby Gilead purchased a minority interest in Tizona and has the exclusive option to acquire the remainder of the company. This collaboration will fund Tizona’s first-in-class programs, such as TTX-080 and TZ-040, as well as other early pipeline programs.

Tizona remains dedicated to translating novel scientific insights into first-in-class immunotherapies and Gilead is a partner who shares our passion for science and delivering breakthrough innovation to patients with cancer.

IRS Form 8937

Issuers of corporate securities are required to complete Internal Revenue Service Form 8937 to report organizational actions that affect the basis of the securities involved in the organizational action. The tax information contained herein is provided for informational purposes only and should not be construed as legal or tax advice. Tizona does not provide legal or tax advice. Please consult your personal tax advisor for assistance as to how this information will impact your specific tax situation.


Internal Revenue Service Form 8937
Shareholders Basis in Recapitalization